| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cyclerion Therapeutics, Inc.$3.22
+0.04 (+1.26%)
D 39Pipeline Score Overvalued Pharma · Clinical
Market Cap
13.77 M
EPS
-1.37
P/E Ratio
-
Value Trade
94.90 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
730.00 K
Operating CF
-1.18 M
Total Assets
8.51 M
Total Liabilities
8.51 M
Equity
6.79 M
D/E Ratio
12,345
3.92 %
Week
4.95 %
1 Month
146.51 %
3 Month
125.53 %
6 Month
-95.02 %
5 Year
-99.19 %
All Time
Cash Data
Cash Position
2.82 M
Monthly Burn
392.00 K
Runway
6.2 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
7.71 K
52 Week Range
1.03 - 8.48
% held by Insiders
25.28 %
% held by Institutions
19.01 %
Enterprise Value
10.95 M
Total Shares
3.93 M
Short %
1.12 %
Float Shares
2.18 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D39
Pipeline Score $6M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.5x
rNPV / MCap Top 57%
Micro Cap (rank 390 of 905)
Percentile RankCyclerion Therapeutics, Inc. faces pipeline headwinds (39/100), with $2.2B risk-adjusted pipeline value, led by IW-1973 in Diabetes Mellitus, Type 2 (Phase 2), across $105B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IW-1973 Small molecule | Diabetes Mellitus, Type 2 | Phase 2 | NCT02906579 | 9% | $1.8B | COMPLETED | 37 | - | - | Mar 17, 2017 | - | Apr 16, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CYCN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Cyclerion Therapeutics, Inc. (CYCN) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CYCN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CYCN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CYCN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CYCN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CYCN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CYCNCyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and Korsana Biosciences have announced a merger agreement, with the combined entity to operate as Korsana Biosciences, Inc. The merger is supported by a significant private investment, expected to fund operations through 2029. The lead program, KRSA-028, targets Alzheimer's disease and aims to advance through clinical trials. The transaction is anticipated to close in Q3 2026, pending shareholder approvals.
Read more →CYCNCyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Cyclerion Therapeutics announced positive feedback from the FDA regarding its CYC-126 Phase 2 proof-of-concept study for treatment-resistant depression. The company is set to initiate the study in the second half of 2026, supported by a newly formed Clinical Advisory Board. This development aims to address significant unmet needs in treating this condition.
Read more →CYCNCyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
Cyclerion Therapeutics has announced a strategic collaboration with Medsteer to advance the development of CYC-126, a novel therapy for treatment-resistant depression. The partnership aims to integrate Medsteer's anesthetic delivery technology into CYC-126, enhancing its precision and effectiveness. The Phase 2 proof-of-concept study is expected to begin in the second half of 2026, with further updates to be shared in an upcoming investor webcast.
Read more →Competitive Position
How CYCN ranks across every disease it competes inCompetitive Position is a premium feature
See how CYCN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial